Hope for long Covid sufferers as new study will trial Pfizer's antiviral Paxlovid in patients - 1br
Paxlovid, the pharma giant's flagship Covid drug, gained emergency approval in the US last December to treat high-risk patients - slashing their risk of death by 90 per cent.
VIEW MORE : https://bit.ly/1breakingnews
VIEW MORE : https://bit.ly/1breakingnews